首页> 美国卫生研究院文献>Journal of Clinical Medicine >Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS
【2h】

Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS

机译:通过突变KRAS将幼稚T细胞表型转换为免疫抑制性Treg样细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oncogenic (mutant) Ras protein Kirsten rat sarcoma viral oncogene homolog (KRAS) promotes uncontrolled proliferation, altered metabolism, and loss of genome integrity in a cell-intrinsic manner. Here, we demonstrate that CD4 T cells when incubated with tumor-derived exosomes from mutant (MT) KRAS non-small-cell lung cancer (NSCLC) cells, patient sera, or a mouse xenograft model, induce phenotypic conversion to FOXP3 Treg-like cells that are immune-suppressive. Furthermore, transfecting T cells with MT KRAS cDNA alone induced phenotypic switching and mathematical modeling supported this conclusion. Single-cell sequencing identified the interferon pathway as the mechanism underlying the phenotypic switch. These observations highlight a novel cytokine-independent, cell-extrinsic role for KRAS in T cell phenotypic switching. Thus, targeting this new class of Tregs represents a unique therapeutic approach for NSCLC. Since KRAS is the most frequently mutated oncogene in a wide variety of cancers, the findings of this investigation are likely to be of broad interest and have a large scientific impact.
机译:致癌(突变)Ras蛋白Kirsten大鼠肉瘤病毒致癌基因同源物(KRAS)以细胞内在的方式促进不受控制的增殖,新陈代谢的改变和基因组完整性的丧失。在这里,我们证明CD4 T细胞与突变(MT)KRAS非小细胞肺癌(NSCLC)细胞,患者血清或小鼠异种移植模型的肿瘤来源外泌体一起孵育时,会诱导表型转化为FOXP3 Treg样具有免疫抑制作用的细胞。此外,仅用MT KRAS cDNA转染T细胞诱导了表型转换,数学模型支持了这一结论。单细胞测序确定干扰素途径是表型转换的基础机制。这些观察结果突出了KRAS在T细胞表型转换中的一种新的非细胞因子依赖性,细胞外源性作用。因此,靶向这类新的Tregs代表了NSCLC的独特治疗方法。由于KRAS是多种癌症中最常见的致癌基因,因此这项研究的发现可能引起广泛的兴趣,并具有重大的科学影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号